CVS vs DMAC · P/E 16, rev $402.07B vs $157.4M cap
CVS Health Corp (CVS) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
DMAC does not have a complete income-statement cache yet.
CVS currently screens at market cap $86.20B and trailing P/E 16.3. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the CVS and DMAC stock pages for the full models.
Not investment advice.